BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17653664)

  • 1. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.
    Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y
    Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity.
    Miao QF; Liu XY; Shang BY; Ouyang ZG; Zhen YS
    Anticancer Drugs; 2007 Feb; 18(2):127-37. PubMed ID: 17159599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
    Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
    Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity.
    Ru Q; Shang BY; Miao QF; Li L; Wu SY; Gao RJ; Zhen YS
    Eur J Pharm Sci; 2012 Nov; 47(4):781-9. PubMed ID: 22982402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
    Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
    Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
    Zheng YB; Shang BY; Li Y; Zhen YS
    Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activities of dFv-LDP-AE: An enediyne-energized fusion protein targeting tumor-associated antigen gelatinases.
    Zhong GS; Wu MN; Guo XF; Zhang SH; Miao QF; Zhen YS
    Oncol Rep; 2012 Oct; 28(4):1193-9. PubMed ID: 22797730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Construction of energized fusion protein consisting of epidermal growth factor receptor oligopeptide ligand and lidamycin and its antitumor activity].
    Guo XF; Zhong GS; Miao QF; Zhen YS
    Ai Zheng; 2009 Jun; 28(6):561-8. PubMed ID: 19635191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
    Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
    Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy.
    Xu J; Liu XJ; Li L; Zhang SH; Li Y; Gao RJ; Zhen YS
    Oncotarget; 2015 Sep; 6(28):26322-34. PubMed ID: 26314845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy.
    Zhang Q; Liu XJ; Hu L; Liao DS; Zheng YB; Zhen YS; Song X
    Int J Mol Med; 2012 Mar; 29(3):409-15. PubMed ID: 22108624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of the assembly efficiency for lidamycin chromophore bound to its apoprotein: a case study using orthogonal array.
    Zhong GS; Guo XF; Zhang SH; Zhen YS
    Biomed Environ Sci; 2011 Dec; 24(6):602-7. PubMed ID: 22365395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma.
    Li L; Huang YH; Li Y; Wang FQ; Shang BY; Zhen YS
    World J Gastroenterol; 2005 Aug; 11(29):4478-83. PubMed ID: 16052675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of the molecule-downsized immunoconjugate composed of lidamycin and Fab' fragment of monoclonal antibody directed against type IV collagenase.
    Fengqiang W; Boyang S; Yongsu Z
    Sci China C Life Sci; 2004 Feb; 47(1):66-73. PubMed ID: 15382678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11].
    Wang FQ; Shang BY; Zhen YS
    Yao Xue Xue Bao; 2003 Jul; 38(7):515-9. PubMed ID: 14515796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antitumor activities of various immunoconjugates composed of lidamycin and anti-type IV collagenase monoclonal antibody].
    Feng Y; Zhen YS; Dai Y; Shang BY; Zhang M; He HW; Li BW; Shao RG
    Yao Xue Xue Bao; 2007 Jul; 42(7):704-9. PubMed ID: 17882952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
    Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
    Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of the antitumor activities of immunoconjugates composed of lidamycin and monoclonal antibody fab' fragment with different linkers].
    Feng Y; Shao RG; Dai Y; Li BW; He HW; Ren KH
    Yao Xue Xue Bao; 2010 May; 45(5):571-5. PubMed ID: 20931757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.